Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions

Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 ...

AstraZeneca’s (AZN) CARES Phase III Clinical Programme Fails to Meet Primary End Point

AstraZeneca PLC (NYSE:AZN) is one of the best stocks to buy now for long term growth. AstraZeneca PLC (NYSE:AZN) reported on ...
U.S. News & World Report

AstraZeneca Therapy for Clearing Protein Deposits Fails Main Goal in Late-Stage Study

(Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, ...

AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus

AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...
Reuters

AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers

June 25 (Reuters) - AstraZeneca's (AZN.L), opens new tab blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a ...
equities

AstraZeneca Rheumatoid Arthritis Drug Fails to Meet Both Primary Endpoints

AstraZeneca PLC (AZN) said on Friday that top-line results from its OSKIRA-1 Phase III testing fostamitinib for rheumatoid arthritis (RA) hit one endpoint, but failed to show a necessary improvement ...
Yahoo

AstraZeneca's breast cancer drug combination fails in late-stage trial

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An AstraZeneca logo is pictured in Brussels (Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in ...